Could a tiny eye implant replace daily drops for glaucoma?

NCT ID NCT06964061

Ongoing Disease control Sponsor: PolyActiva Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-stage trial is testing a single biodegradable implant placed in the eye to lower pressure in people with open-angle glaucoma or ocular hypertension. The implant slowly releases medication over time and then dissolves. The study includes 12 adults and focuses on safety, how well it works, and how long it takes to break down.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PA5346 ocular implant (a biodegradable device that releases medication to lower eye pressure)
What this could lead to: If it works, this could lead to a new treatment option that lowers eye pressure for months with a single implant, reducing the need for daily eye drops.
What could go wrong: This is a very early (Phase 1) trial with only 12 people, so it is too small to prove effectiveness. The implant may not work as hoped or could cause side effects like eye irritation or vision changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION (OH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OCULAR HYPERTENSION (OH) OPEN-ANGLE GLAUCOMA (OAG)

Contacts and locations

Locations

Cataract & Eye Surgery Centre

Doncaster, Victoria, 3109, Australia
Melbourne Eye Specialists

Melbourne, Victoria, 3000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.